Revisiting potential value of antitumor drugs in the treatment of COVID-19

Zheng, Wenfang; Zeng, Zekun; Lin, Shumei; Hou, Peng

doi:10.1186/s13578-022-00899-z

Cell & Bioscience

Table 1 Summary of potential anticancer drugs in the treatment of COVID-19

From: Revisiting potential value of antitumor drugs in the treatment of COVID-19

Class	Mode of action	Target	Agent	Clinical trial	Refs
Inhibition of viral entry	Inhibition of viral entry and endosome trafficking	PIKfyve	Apilimod	NCT04446377	[41]
Inhibition of viral entry	Allosterically inhibiting the binding of ACE2 to S protein	ACE2	Imatinib	NCT04394416 NCT04953052 NCT04794088	[52]
Interference with the viral cycle	Inhibition of protein translation	eIF4A	Zotatifin	NCT04632381	[56]
	Inhibition of protein translation	eEF1A2	Plitidepsin	NCT04382066 NCT04784559	[59]
	Blockade of viral replication	FASN	TVB-2640	NA	[66]
		Folate metabolism	Methotrexate	NCT04610567	[33]
		CK2	Silmitasertib	NCT04663737 NCT04668209	[76]
		mTORC1	Rapamycin	NCT04341675 NCT04948203 NCT04461340	[82]
	Competitive inhibition of Mpro	Mpro	Masitinib	NCT05047783	[84]
Inhibition of overactivated inflammatory responses	Blockade of excessive cytokines	IL-6	Tocilizumab	NCT04356937 NCT04320615 NCT04372186 NCT02735707	[108, 109]
		JAK	Tofacitinib	NCT04750317 NCT04469114	[117]
			Baricitinib	NCT04358614 NCT04421027 NCT04362943 NCT04401579 NCT04640168	[118]
			Ruxolitinib	NCT04334044 NCT04362137 NCT04338958 NCT04374149 NCT04359290	[119]
		TNF-α	Thalidomide	NCT04273581 NCT04273529	[24]
		TNF-α	Lenalidomide	NCT04361643	[24]
		TOP1	Topotecan	NCT05083000	[131]
	Activation of innate immune response	STING	diABZI	NA	[97]
	Inhibition of the production of active neutrophil	Neutrophils	Corticosteroids	NCT04530409 NCT04726098 NCT04355637 NCT05004753	[124]
	Inhibition of the production of proinflammatory cytokines from immune cells	BTK	Ibrutinib	NCT04375397 NCT04439006 NCT04848493	[138]
			Acalabrutinib	NCT04647669 NCT04497948 NCT04380688 NCT04665115	[139]
			Zanubrutinib	NCT04382586	[139]
	Inhibition of angiogenesis	VEGF	Bevacizumab	NCT04275414 NCT04822818	[128]

S protein Spike proteins; PIKfyve Phosphatidylinositol 3-phosphate 5-kinase; ACE2 Angiotensin-converting enzyme 2; eIF4A Eukaryotic translation initiation factor 4A; eEF1A2 Eukaryotic translation elongation factor 1 alpha 2; FASN Fatty acid synthase; CK2 Casein kinase II; mTORC1 Mammalian target of rapamycin complex 1; Mpro The main protease; IL-6 interleukin-6; JAK Janus kinase; TNF-α Tumor necrosis factor-alpha; TOP1 Topoisomerase 1; STING Signaling effector stimulator of interferon genes; diABZI Dimeric amidobenzimidazole; BTK Bruton’s tyrosine kinase; VEGF Vascular endothelial growth factor

Back to article page

ISSN: 2045-3701

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com